GeneGo Receives Phase II SBIR from NCI SBIR to Develop Integrative Cancer Data Analysis Platform | GenomeWeb

GeneGo said today that it has been awarded a Phase II Small Business Innovation Research grant from the National Cancer Institute to continue the development of its MetaMiner (Oncology) platform.

The award is worth $625,485 according to an NIH database. It follows a $200,000 Phase I SBIR that the company was awarded in 2008 to adopt its MetaMiner pathway analysis platform for cancer research (BioInform 6/20/2008).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.